The Gross Law Firm Announces Class Actions on Behalf of Shareholders of DOX, ACAD and PRVB
Back to Newsroom
Mentioned in this Article

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of DOX, ACAD and PRVB

Tuesday, June 8, 2021 11:00 AM
Share this article now
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / June 8, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Amdocs Limited (NASDAQ:DOX)

Investors Affected : December 13, 2016 - March 30, 2021

A class action has commenced on behalf of certain shareholders in Amdocs Limited. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Amdocs overstated its profits, cash, and liquidity, while understating its debt; (ii) Amdocs concealed its large borrowing; (iii) while Amdocs' reported results showed that its North American business was stable, that business was actually deteriorating annually, in part because the Company was losing AT&T as a customer; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/amdocs-limited-loss-submission-form/?id=16681&from=1

Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)

Investors Affected : June 15, 2020 - April 4, 2021

A class action has commenced on behalf of certain shareholders in Acadia Pharmaceuticals Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the materials submitted in support of the pimavanserin supplemental new drug application (sDNA) contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the Food and Drug Administration Agency was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/acadia-pharmaceuticals-inc-loss-submission-form/?id=16681&from=1

Provention Bio, Inc. (NASDAQ:PRVB)

Investors Affected : November 2, 2020 - April 8, 2021

A class action has commenced on behalf of certain shareholders in Provention Bio, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the teplizumab Biologics License Application ("BLA") was deficient in its submitted form and would require additional data to secure U.S. Food and Drug Administration approval; (ii) accordingly, the teplizumab BLA lacked the evidentiary support the Company had led investors to believe it possessed; (iii) the Company had thus overstated the teplizumab BLA's approval prospects and hence the commercialization timeline for teplizumab; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/provention-bio-inc-loss-submission-form/?id=16681&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm
 

The Gross Law Firm
Back to Newsroom
Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions